Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review (vol 11, pg 1, 2019)

被引：0
|
作者：
Chiorean, Elena Gabriela
Cheung, Winson Y.
Giordano, Guido
Kim, George
Al-Batran, Salah-Eddin
机构：
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2019年 / 11卷
关键词：
D O I：
10.1177/1758835919871363
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
    Chiorean, Elena Gabriela
    Cheung, Winston Y.
    Giordano, Guido
    Kim, George
    Al-Batran, Salah-Eddin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [2] A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
    Wang, Ying
    Camateros, Pierre
    Cheung, Winson Y.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (01) : 62 - 68
  • [3] A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
    Ying Wang
    Pierre Camateros
    Winson Y. Cheung
    Journal of Gastrointestinal Cancer, 2019, 50 : 62 - 68
  • [4] Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan
    Maeda, O.
    Yokoyama, Y.
    Yamaguchi, J.
    Ota, A.
    Matsuoka, A.
    Morita, S.
    Inoue, M.
    Mizutani, T.
    Shimokata, T.
    Urakawa, H.
    Mitsuma, A.
    Nagino, M.
    Ando, Y.
    ANNALS OF ONCOLOGY, 2017, 28 : 69 - 69
  • [5] Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)
    Chiorean, E. G.
    Cheung, W. Y.
    Giordano, G.
    Kim, G.
    Al-Batran, S-E.
    ANNALS OF ONCOLOGY, 2018, 29 : 245 - 246
  • [6] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [7] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
    Yamamoto, Shun
    Ueno, Hideki
    Tanaka, Midori
    Inagaki, Yuji
    Ohba, Akihiro
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Morizane, Chigusa
    Okusaka, Takuji
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
    Arciero, Vanessa
    Luo, Jin
    Parmar, Ambica
    Dai, Wei Fang
    Beca, Jaclyn M.
    Raphael, Michael J.
    Isaranuwatchai, Wanrudee
    Habbous, Steven
    Tadrous, Mina
    Earle, Craig C.
    Biagi, Jim J.
    Mittmann, Nicole
    Arias, Jessica
    Gavura, Scott
    Chan, Kelvin K. W.
    JNCI CANCER SPECTRUM, 2022, 6 (04)
  • [9] Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans
    Sigel, Keith
    Zhou, Mengxi
    Park, Yeun-Hee Anna
    Mutetwa, Tinaye
    Nadkarni, Girish
    Yeh, Celine
    Polak, Paz
    Sigel, Carlie
    Conroy, Thierry
    Juzyna, Beata
    Ychou, Mark
    Fojo, Tito
    Wisnivesky, Juan P.
    Bates, Susan E.
    SEMINARS IN ONCOLOGY, 2021, 48 (01) : 69 - 75
  • [10] Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.
    Sharif, Shahriar
    Zureikat, Amer H.
    Novelli, Paula M.
    Lopez, Charles D.
    Kardosh, Adel
    Chung, Ki Y.
    Jones, Wesley B.
    Hatoum, Hassan
    Meredith, Kenneth Lee
    Zervos, Emmanuel E.
    Ucar, Antonio
    Gandhi, Ripal T.
    Nazemzadeh, Reza
    Kasi, Pashtoon Murtaza
    Vandestraeten, Erik
    Decaestecker, Jochen
    Delaunoit, Thierry
    Li, Charles Charles
    Agah, Ramtin
    Pishvaian, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345